The National Institute of Cancer (INCan), a Mexican oncologic center, is the first in the country to offer positron emission mammography (PEM), which is a breast application of Naviscan's PET scanner that shows the location as well as the metabolic phase of a lesion.

The PEM scanner, which is an FDA-cleared 3D molecular breast imaging device, characterizes breast cancer, assists surgical planning, monitors patient response to chemotherapy and evaluates suspected recurrence, according to San Diego-based Naviscan.